The eighth International Mesothelioma Interest Group (IMIG) meeting was held in Chicago, IL, United States, in 19-22 October 2006 to discuss mesothelioma -the cancer often linked to asbestos exposure. It is a very aggressive malignancy with a median survival of less than 1 year from diagnosis. Millions of people have been exposed worldwide to asbestos, especially during the second half of the twentieth century when asbestos use increased significantly. The tons of asbestos utilized in the past remain a health hazard for current and future generations because asbestos is difficult to be disposed off. This makes asbestos and mesothelioma research a public health issue in addition to a medical problem. Moreover, the very high costs of asbestos litigation have a significant impact on the whole economy. In the United States, up until 2001, defendant companies had paid 54 billion dollars in claims and estimated future liabilities ranged from 145 to 210 billion. Therefore, asbestos research is of great interest to a large audience that includes patients, millions of asbestos-exposed individuals, scientists, physicians, public health officials, politicians, unions of asbestos workers, lawyers and the public at large. During the past few years, there has been significant progress in understanding the process of mineral fiber carcinogenesis and mesothelioma pathogenesis. With improved understanding of the pathogenesis of mesothelioma, new diagnostic, preventive and therapeutic options are being developed. A total of 247 papers were presented at the IMIG: the abstracts of these presentations were published in Lung Cancer, Supplement 1, October 2006. Here, experts in different disciplines critically review some of the most exciting presentations of the IMIG meeting. The result is a comprehensive review of the research field of asbestos carcinogenesis and mesothelioma, and of the progress that has been made in recent years in both basic and clinical sciences. Genetics and Gene-environment interaction The opening lecture was by M Carbone, who presented the work that he is conducting in Cappadocia, Turkey, where three villages experience a very high incidence of mesothelioma (over 50% of all deaths are caused by mesothelioma). Carbone et al. (2007) discovered that genetic predisposition to erionite, a type of mineral fiber similar to asbestos, is the cause of this epidemic. These researchers are now attempting to isolate the putative mesothelioma susceptibility gene that makes certain families unusually susceptible to mineral fiber carcinogenesis. Moreover, to reduce the exposure to erionite and the incidence of mesothelioma, and upon request of this team of scientists, the Turkish government has built a new erionite-free village that will open in the summer of 2007. In addition, recent serological testing for mesothelin and Osteopontin -see the section by HI Pass -has led to the identification of early mesothelioma cases in Cappadocia. Early detection poses ethical problems for how best to treat patients if the disease is undetectable radiologically. A chemopreventive clinical trial is now in the works. Alfacell, a company that produces Onconase -see section by A Tsao -a drug that has limited side effects and that has proven beneficial in some mesothelioma patients -is preparing a subcutaneous formula to be tested in high-risk individuals in Cappadocia (that is, individuals found to have high levels of mesothelin or osteopontin). The Turkish government will provide the support for clinical testing and follow-up of these patients (the ethical issues are discussed in Carbone et al., 2007) . The results of the early detection serological trial (osteopontin and mesothelin), and of the chemopreventive trial (Onconase), are of obvious potential significance for millions of asbestos-exposed workers that are at risk for mesothelioma.
MC Jaurand documented the genetic alterations resulting from asbestos exposure in a comparative study between human mesothelioma and asbestos-induced murine mesothelioma. Results argue for a specific DNA damage profile. Comparative analysis of tumor suppressor genes, P53 and genes located at the INK4 locus (P16/CDKN2A, P14/ARF, P15/CDKN2B) demonstrated similar frequency of alteration in 40 early passages of human mesothelioma as in 11 early passages of ascites from murine mesotheliomas developed in hemizygous Nf2 þ /À mice exposed to crocidolite fibers (Leconte et al., 2005) . Mutational analysis by genomic DNA sequencing showed that G to T transversions were not commonly found in P53, and that genes at the INK4 locus were inactivated by deletion, both in human and in mice. These results are consistent with the data reported in human tumors, and with various literature demonstrating that chromosome breakage, LOH and chromosomal deletion are found in mammalian cells exposed to asbestos fibers.
Distinct genetic alterations in asbestos-exposed subjects were reported by P Lindholm (Finland). These authors analysed gene copy number in patients with lung cancer either heavily exposed (14 tumors) or not exposed to asbestos (14 matched tumors), and in patients with pleural mesothelioma (20 cases). A comparative genomic hybridization study revealed 18 regions on chromosomes 2p21-p16.3, 5q35.3, 9q33.3-q34.11, 9q34, 13-q43.3, 11p15.5, 14q11.2 and 19p13.1-p13 .3 associated with cancer from either asbestosexposed or nonexposed patients.
Analysis of gene profiling allowed S Varghese et al. (USA) to identify mesothelin, epithelial growth factor receptor (EGFR) and insulin growth factor-1 (IGF-1) as genes consistently overexpressed in peritoneal mesothelioma in comparison with normal peritoneum. R Bueno and collaborators (USA) had previously proposed the use of a gene ratio-based test to predict patient survival after multimodality therapy (Gordon et al., 2005) . The authors prospectively validated this test with 45 patients. This test was found to be reproducible and accurate for samples containing as low as 5% of tumor cells.
These data are in contrast to those of M Ladanyi's laboratory (USA), who found that the accuracy of these microarrays is consistently lower than reported by Bueno and by others, and that their power in clinical prognostication has been overestimated (Lopez-Rios et al., 2006) . JR Testa and colleagues (USA) exposed heterozygous Nf2 knockout mice to asbestos by intraperitoneal injection. Induction of mesothelioma was accelerated in asbestosexposed Nf2 ( þ /À) mice as compared to wild-type littermates injected with asbestos. Loss of the wild-type Nf2 allele, leading to biallelic inactivation, was observed in all nine tested mesotheliomas from Nf2 ( þ /À) mice and in two of five (40%) asbestos-induced mesotheliomas from wild-type mice. Like in human mesotheliomas, tumor cells from Nf2 ( þ /À) mice showed frequent homozygous deletions encompassing the Cdkn2a/Arf and Cdkn2b loci, as well as reciprocal inactivation of p53 in a smaller subset of tumors that retained the Arf locus. Furthermore, as in the human disease counterpart, mesotheliomas from the Nf2 knockout mice showed frequent activation of Akt and Erk, which could be suppressed by selective, targeted inhibitors. The involvement of similar somatic genetic and cell signaling perturbations in human mesothelioma and this murine model suggests that specific molecular events may be critical to mesothelial cell tumorigenesis .
Apoptosis
Mesothelioma is highly resistant to current therapies, a resistance thought to be due to a resistance to induction of apoptosis by chemotherapy and radiotherapy. Consideration of the complex pathways of apoptosis and the equally complex system of survival signaling is uncovering potential targets for therapy in mesothelioma. The path forward is twofold: to understand the critical intervention points in the apoptotic pathways and to understand the modes of resistance used by mesothelioma. The BH3-only family of proteins provides a rich array of protein-protein interactions that can be targeted, as discussed by D Fennell (UK). It has nonetheless been difficult to find specific and high affinity inhibitors for such interactions. With a structure-based drug design strategy based on nuclear magnetic resonance screening, S Rosenberg (USA) described the development of potent small molecules targeting Bcl-XL, Bcl-2 and Bcl-w, with in vitro evidence of the enhancement of cytotoxic drugs on many cancer cell line. Recently, one of these compounds has shown in vivo evidence of activity against established tumors in mice (Shoemaker et al., 2006) . Another more indirect approach is to overcome resistance mechanisms by activating two different apoptotic pathways that converge at the mitochondria. C Broaddus discussed the concept of synergistic interaction of two apoptotic pathways, the death receptor (extrinsic) and the damage (intrinsic) pathways. In this approach, the damage signal primes the mitochondria to respond to the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) signal tBid and appears to bypass or overwhelm resistance mechanisms of the tumor (Broaddus et al., 2005) .
Signals proximal to the mitochondria however may prevent apoptotic signals from reaching the mitochondria and thus can promote survival even when antiapoptotic mechanisms are inactivated at the level of the mitochondrial proteins. Proximal signals may include inhibitors of proximal apoptotic signals such as FLIPs and the survival pathways such as Akt, both of which have been reported to be important in mesothelioma. G Gaudino (Italy) spoke of the Akt/mTOR pathway and its role both in the initial transformation of mesothelial
cells by asbestos (Cacciotti et al., 2005) and in the ongoing survival of mesothelioma. Various critical receptor tyrosine kinase pathways hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) may utilize Akt as a common critical pathway, and inhibitors of Akt and mTOR show promise for inducing apoptosis, either alone or in combination with other pro-apoptotic approaches. D Jablons (USA) discussed the Wnt pathway, as an intriguing potential target in mesothelioma (Mazieres et al., 2005) . Normally active in development and dormant in adult tissues, the Wnt pathway is critical for stem-cell renewal and tissue regeneration. Wnt signaling is active in mesothelioma and may be critical for mesothelioma survival and resistance to therapy. Even putative pro-apoptotic molecules may normally function as survival factors only to be induced to become pro-apoptotic in certain circumstances, as discussed by M Peter (USA) for the role of fas. The death receptor CD95 (Fas/Apo-1) has many nonapoptotic functions and may be primarily a tumor promoter. It is not yet known if this is a feature of mesothelioma, but it challenges assumptions about the function of molecules assumed to be pro-or antiapoptotic.
A general mechanism of resistance covered by D Barbone (USA) is multicellular resistance, induced when cells aggregate into three-dimensional structures. Mesothelioma, a tumor with significant matrix components, may be expected to show this acquired, multicellular resistance due to its stroma and architecture, as has also been shown in tumor fragment spheroids grown from this tumor (Kim et al., 2005) . Indeed, mesothelioma cell lines acquire significant resistance when allowed to form into three-dimensional structures called multicellular spheroids.
Strategies in apoptosis may require a combinatorial approach in which anti-apoptotic mechanisms are disarmed while pro-apoptotic stimuli are activated. The most promising approaches for blocking antiapoptotic mechanisms may be those that act directly at the mitochondria. Then, even though mesothelioma may utilize multiple or shifting survival strategies, a direct approach to the main apoptotic organelle may tip the balance toward apoptosis.
Pathogenesis: asbestos
Human mesothelial cells in culture are not transformed by asbestos, instead they become apoptotic or are lysed. This issue -how could crocidolite cause mesothelioma if human mesothelial cells exposed to asbestos fibers diehas puzzled investigators for years. H Yang (USA) discovered that crocidolite asbestos induces human mesothelial cells to release tumor necrosis factor-a (TNF-a), and to express the TNF-a receptor. Exposure of mesothelial cells to TNF-a significantly reduced crocidolite cytotoxicity. This protective effect was caused by TNF-a mediated NF-kB activation which in turn inhibited crocidolite-induced cytotoxicity and increased the numbers of human mesothelial cells that survived crocidolite exposure and thus the percentage of cells that could become transformed. Inhibition of NF-kB with Bay11-7082, a chemical compound that blocks the phosphorylation of IkB, suppressed the protective effect of TNF-a on crocidolite cytotoxicity. The results were verified with RNA interference assays using shRNA-RelA constructed with lentivirus to knock down NF-kB-RelA expression. The results confirmed that NF-kB is required for TNF-a mediated cytoprotection. Therefore, in the presence of TNF-a, mesothelial cells that have accumulated genetic damage because of asbestos exposure may be more prone to divide than to die and this may lead to mesothelioma. Cytogenetic studies supported this interpretation showing that TNF-a protected human mesothelial cells from asbestos-induced genetic damage . L Mutti, (Italy), independently confirmed the critical role of NF-kB in mesothelial cell transformation. Mutti found that NF-kB signaling was significantly increased in transformed human mesothelial cells and in mesothelioma cell lines, compared to primary mesothelial cells. Inhibition of NF-kB signaling increased asbestos cytotoxicity. Mutti concluded that NF-kB plays a significant role in contributing to mesothelial cell transformation by making mesothelial cells resistant to asbestos induced cytotoxicity and proposed that targeting NF-kB signaling, for example with Onconase, may lead to more effective therapeutic approaches.
Pathogenesis: SV40
A multilaboratory study (Testa et al., 1998) , conducted upon IMIG request, was supposed to resolve the issue concerning the association of SV40 with mesothelioma. That study found that most US mesothelioma tested contained SV40 DNA sequences (Testa et al., 1998) . Since then the controversy about the presence and role of SV40 in mesothelioma pathogenesis has not subsided, and the issue has become almost as controversial as the issue that surrounds the carcinogenicity of chrysotile, a type of asbestos that some argue is not carcinogenic. As is the case for chrysotile, the controversy concerning SV40 is fueled by both scientific and economical reasons. Linking SV40 to mesothelioma pathogenesis has the potential to influence the multibillion dollar litigation associated with asbestos and mesothelioma (Lagnese, 2005) . Moreover, SV40 is an economic liability for the pharmaceutical companies that manufactured SV40-contaminated polio vaccines and that are now been sued by patients with SV40-positive tumors (Bookchin and Schumacher, 2004) . The IMIG meeting hosted an entertaining debate between A Gazdar (USA), who argued that SV40 is a factor in the pathogenesis of human mesothelioma, and M Ladanyi (USA) who argued that SV40 is not a factor at all. The scientists presented two completely opposite views of the data leaving the audience with the difficult task of deciding how to reconcile diametrically opposite findings. Ladanyi, presented the results of his paper (Lopez-Rios et al., 2004) stating that initially they found that approximately 60% of the 71 mesothelioma tested contained SV40, but that subsequent analyses indicated that plasmid contamination of his laboratory caused the positivity and that the 71 samples were all SV40 negative. (However, in his manuscript M Ladanyi stated that after ruling out plasmid contamination, four samples (6%) remained SV40-positive.) Ladanyi concluded that if his laboratory was contaminated, other laboratories that reported detection of SV40 were also likely contaminated by plasmids. He advocated the use of primers outside the transforming region of SV40, said that positivity for SV40 Tag can be nonspecific and concluded that further studies on this issue are not needed and that all research investigating the association of SV40 with human cancer should be stopped.
Gazdar, disagreed with the suggestion of using only primers outside the transforming region, because this is the region required for oncogenesis and if such an approach had been used, many human DNA tumor viruses, such as human papillomavirus, would not have been linked to human cancer. He noted that a recent multi-laboratory study had shown that PCR detection of SV40 was highly reliable when strict precautions were taken to prevent or to detect possible plasmid or viral contamination, and suggested that other investigators use the same methodology (Cutrone et al., 2005) . Gazdar argued that his own microdissection studies had specifically linked SV40 to the malignant mesothelioma cells and not to the nearby nonmalignant cells. He noted that it would be impossible to consider these findings a laboratory artifact because tumor and nontumor cells had been microdissected in parallel from the same slides. Gazdar noted that even if Ladanyi's laboratory was contaminated, his laboratory was not. He underscored that there was an overwhelming number of reports from many different laboratories confirming the presence of SV40 in mesothelioma (reviewed in Gazdar et al., 2002) . Gazdar conducted a statistical analysis of all the published data that included negative control tissue and found that it was statistically impossible that all the positive findings were caused by contamination (that is SV40 would always be detected in the tumor biopsy and not in the negative controls).
M Carbone presented data showing that SV40 and crocidolite asbestos are cocarcinogens in human cells in tissue culture and in hamsters . Asbestos alone caused mesothelioma in 20% of hamsters, but when the hamsters were exposed to asbestos and infected with SV40, 90% of the animals developed mesothelioma and the latency was shorter. In these experiments, to avoid the possible confounding effect caused by SV40, the authors used a mutant of SV40 that, per se, does not cause mesothelioma. In parallel studies in primary human and primary hamster mesothelial cells in tissue culture, these investigators elucidated the mechanisms of cocarcinogenesis and demonstrated that the mechanisms were identical in both human and hamster mesothelial cells. They showed that SV40 and asbestos synergistically activated specific members of the AP-1 pathway causing cell division and invasion into a matrix gel. RNA interference and chemical inhibitors were used to prove the specificity of these pathways in mesothelial cell cocarcinogenesis. This is the first in vivo study showing that viruses (SV40) and mineral fibers (asbestos) can be cocarcinogens. The results provide a possible rationale for the observation that among individuals exposed to asbestos or SV40, only few develop mesothelioma. Individuals that are exposed to both carcinogens may be at higher risk. Moreover, low doses of asbestos that by themselves are not oncogenic caused mesothelioma in animals infected with SV40, suggesting that, in humans, the risk of mesothelioma may vary depending on history of exposures. A recent epidemiological study found that among asbestos-exposed individuals, those who were infected with SV40 were at higher risk of developing mesothelioma than those not SV40-infected (odds ratio (OR) for AsbÀ SV40 þ patients, 0.4; Asb þ SV40-3.6; Asb þ SV40 þ , 12.6; Cristaudo et al., 2005) .
RA Lake (Australia) created transgenic mice that express the SV40 Tag in the mesothelial cells under the control of the mesothelin promoter. These mice had a higher risk of developing mesothelioma when exposed to asbestos, and the transgenes that contained a higher copy number were at the highest risk (Robinson et al., 2006) . Pietruska and Kane (2007) (USA) found that SV40 may contribute to mesothelioma progression by circumventing stress-induced senescence in cells exposed to asbestos in part through p53 inactivation. Expression of SV40 oncoproteins abrogated asbestos-induced senescence and enhanced proliferation of cells surviving asbestos exposure. Together the results from these three research teams open a new exciting research field to study the interaction among mineral fibers and viruses in mesothelioma and in human carcinogenesis.
II. Immunology and immunotherapy of mesothelioma. Steven Albelda and Bruce Robinson
There is good evidence that the human immune system can recognize mesothelioma. B Robinson noted that this evidence includes: (1) reports of spontaneous remissions, (2) high titers (>1:100) of antibodies reactive with mesothelioma cell lysates in up to 40% of patients and (3) many anecdotal reports of response of the disease to immunotherapies such as interferon (IFN)-a, IFN-g and interleukin-2. DH Sterman (USA) reported that a recent phase 1 trial using intrapleural IFN-b expressed by an adenoviral vector has shown consistent anti-mesothelioma humoral responses (including antibody responses to SV40 large T-antigen and mesothelin), as well as encouraging clinical responses.
R Lake reported that chemotherapy-induced cell killing that results in 'immunogenic' cell death can deliver large amounts of tumor antigens that can be potentially used to prime the immune system. This principally occurs via apoptosis induction and the delivery of antigens into the cross-presentation pathway. By first treating mesothelioma tumors with gemcitabine (to release tumor antigens) and then activating the immune system with an agonistic anti-CD40 antibody, very strong antitumor immune responses can be generated which induced tumor regressions and cured 50-80% of mice.
Eighth International Mesothelioma Interest Group
M Carbone et al S Albelda proposed that immunotherapies against mesothelioma could be markedly augmented by targeting the tumor-associated macrophages and described a number of approaches that had been successful in animal models including the use of cyclooxygenase-2 inhibitors, a macrophage-activating agent called DMXAA, and inhibitors of the macrophage-produced immunosuppressant TGF-b. H Schreiber (USA) emphasized the importance of the tumor stroma in the development and destruction of tumors. In addition to the adenovirus-IFN-b immunogene therapy trial, a number of immunotherapy clinical trials were described. R Hassan (USA) described promising results from a phase I trial using a monoclonal antibody against the mesothelioma tumor antigen mesothelin coupled to Pseudomonas exotoxin. J Hegmans (Netherlands) presented early data about a dendritic cell vaccine (pulsed with mesothelioma cell extracts) that is being initiated in the Netherlands.
In summary, strong preclinical data and clear evidence of immunogenicity in early human trials suggest that mesothelioma represents an excellent target for the development of immunotherapy. Any immunotherapy trial for mesothelioma would need to be integrated with other standard therapies.
III. Epidemiology. Gunnar Hillerdal and Kristina Kjaerheim
Despite an established etiologic factor explaining a large majority of the occurring cases, many questions remain and were elucidated at the conference. The following three areas stood out: (1) The relative risk according to such variables as duration of exposure and time since first exposure, and type of asbestos or mineral fiber exposure. (2) Public health issues, that is legislation regarding handling and compensation of asbestos in developed and developing countries. (3) Possible cofactors, such as genetics and SV40.
Exposure to asbestos can be occupational or environmental. P Rolland (France) found that the attributable fraction from occupational asbestos exposure in France was 83.2% in men and 41.9% in women. J Peto (UK) reported that a case-control study in the United Kingdom showed that for women, the attributable fraction for occupational exposure to asbestos was 6%, for household exposure 37% and for environmental exposure 20%. The reason for the discrepancy between the countries is unclear.
J Peto reported that, in Britain, a new case-control study found carpenters to be at a specifically high risk for mesothelioma (OR associated with more than 5 years of asbestos exposure before the age of 35 was 33.8, 95% confidence interval (CI) 17.0-67.2), as were plumbers, electricians, painters and decorators (combined OR 12.2, 95% CI 7.2-20.8) and other construction workers (OR 3.9, 95% CI 2.0-7.8). For other high-risk occupations the combined OR was 12.8 (95% CI 7.2-22.6). Lifetime risk for men born around 1950 having worked in these occupations ranged from 1 to 5%, compared to about 1 in 600 in the reference group. P Rolland reported that in France, the highest risks for mesothelioma were seen among plumbers, pipe fitters, sheet-metal workers and those in industries involved in ship repair, asbestos products, metal products and construction. In developed countries, however, it is foreseen that future exposure is more likely among workers in small demolition and rehabilitation firms.
K Kjaerheim presented the results of a case-control study in which pre-diagnostic serum samples were analysed for the presence of antibodies against SV40 by a panel of serological methods. The use of an antibody capture assay while blocking the closely related human polyomaviruses BK and JC showed that the risk of mesothelioma was 50% higher in the group testing positive for antibodies against the SV40 VP-1 capsid protein (OR 1.5, 95% CI 0.89-2.53). When neutralization assays were performed on sera preabsorbed with BKV/JCV, however, no neutralization activity was seen, suggesting an absence of SV40-specific antibodies that do not cross-react with JCV or BKV.
IV. Imaging. Raja Flores
Computed tomography (CT) Figure 1 and magnetic resonance imaging (MRI) (Figure 2 ) are used to identify distant metastasis and to determine surgical resectability. Although CT and MRI provide anatomical information, positron emission tomography (PET) provides physiologic information (Figure 3 ). Tumors with a higher metabolic rate and theoretically a greater propensity to spread take up more radioactive tracer (F-18 fluorodeoxyglucose) while benign or less aggressive lesions take up less tracer. RM Flores reported a direct relationship between increasing PET standardized uptake value (SUV) and poor survival. In a multivariate analysis, SUV greater than 10, stage III and IV disease and nonepithelioid histology were associated with poor survival. (Robinson et al., 2003) and osteopontin (OPN) (Pass et al., 2005) were the subject of a number of investigations presented at the meeting.
J Creaney (Australia) expanded on their original work with SMRP by examining the value of combinatorial markers including SMRP, CA125 and N-ERC (MPF) in distinguishing effusion and serum samples from patients with mesothelioma versus controls from the Australian Mesothelioma Tissue Bank. Of the three assays, SMRP had the highest sensitivity for mesothelioma (ranging from 50% at diagnosis to 70% in end-stage disease). The data suggested that SMRP levels may be elevated in effusions before the cytological detection of malignant cells. K Fukuoka (Japan) found that mesothelioma had significantly elevated SMRP levels compared with those in nonasbestos-exposed controls (5.7 nM versus 0.6 nM), with a sensitivity of 56% for pleural mesothelioma and a specificity of 96%. A problem with this study was the lack of asbestos-exposed controls.
OD Roe (Norway) presented data on levels of SMRP, CA125 and CYFRA 21-1 in banked sera on from 49 subjects that developed mesothelioma 1-30 years later compared to 147 cancer-free, matched controls. Biomarker levels measured in sera from 10 to more than 20 years before mesothelioma were not significantly associated with an increased risk for mesothelioma. The general conclusion was that these markers may be elevated insignificantly years before mesothelioma develops, but cannot predict for the development of mesothelioma. HI Pass presented preliminary studies conducted in Cappadocia (Carbone et al., 2007) . SMRP and osteopontin enzyme-linked immunosorbent assays were performed on sera from patients who lived in some villages where the mesothelioma rate approaches 50%. Superb sensitivity and specificities (86 and 88%, respectively) were seen for SMRP when comparing 21 MM patients with more than 60 erionite-exposed individuals. Moreover, both OPN and SMRP had excellent specificity and sensitivity (96% and 100; 89 and 88%, respectively) when levels were determined on serum from 7 MMs and 72 non-MM villagers, which had been stored for 12 years. These promising findings will hopefully be validated soon. Moreover, a chemoprevention trial in this Cappadochian population, based on rising longitudinal levels of SMRP and OPN using novel formulations of the RNAse Onconase (Alfacell), is being planned with the support of the Turkish Ministry of Health.
VI. Clinical therapy. Anne Tsao
Chemotherapy for mesothelioma The current standard therapy for chemo-naive unresectable malignant pleural mesothelioma is the combination of cisplatin and pemetrexed. The carboplatin (AUC 5) and pemetrexed (500 mg/m 2 ) regimen was studied in several trials and demonstrated reasonable activity. GL Ceresoli (Italy) presented the results in 178 chemo-naive patients. The overall response rate was 22% (5 complete Single agent chemotherapy J Margery (France) reported that Vinoflunine at 320 mg/ m 2 given intravenously every 3 weeks to 65 patients with mesothelioma had a 13.8% response rate, median progression-free survival of 3.2 months and overall survival of 10.8 months. The main grade 3-4 toxicities were neutropenia, injection site reactions, constipation, fatigue, abdominal pain and myalgia.
Salvage chemotherapy
Currently, there is no standard salvage regimen for mesothelioma. JB Sorensen (Denmark) found that pemetrexed may have clinical efficacy in the pretreated population. A total of 28 patients were treated with pemetrexed and 11 with carboplatin pemetrexed with similar results: 21% partial response, median time to progression of 21 weeks and median survival of 28 weeks.
PA Zucali (Italy) found that 28 patients treated with gemcitabine-vinorelbine had a response rate of 7.4% and a median time to progression of 2.8 months.
Anti-angiogenic agents Besides intravenous bevacizumab, there are several oral multi-kinase inhibitors including inhibitors of the VEGF/VEGFR, Raf kinase and platelet-derived growth factor (PDGF)-b pathway that have been investigated in mesothelioma. PA Janne (USA) reported that the phase II trial (CALGB 30307) using sorafenib at 400 mg twice daily in chemo-naive or previously treated pemetrexed patients had a grade 3-4 side effect profile inclusive of 25% fatigue and 13% hand-foot syndrome, an overall response rate of 4.4% and median overall survival of 10.4 months. This trial did not meet its primary endpoint, but correlative studies are underway to determine which patients may have clinical benefits.
Ribonuclease inhibitors
Ranpirnase specifically targets tumor cell tRNA and inhibits protein synthesis with cell cycle arrest at the G 1 phase. This mechanism makes ranpirnase a valuable synergistic agent when used in combination with other cytotoxic drugs. Ranpirnase has a favorable side effect profile with only hypersensitivity, renal toxicity (proteinuria, azotemia), fatigue and peripheral edema making this drug a possible candidate for chemopreventive trials in high-risk-mesothelioma cohorts.
A phase III trial (n ¼ 105) compared ranpirnase (480 mg/m 2 weekly) to doxorubicin (60 mg/m 2 every 3 weeks) and showed no difference in overall survival. However, a significant imbalance in patient demographics was noted with a larger proportion of the CALGB poor risk (groups 5-6) patients included in the ranpirnase arm. Analysis of only the CALGB prognostic groups 1-4 patients showed that ranpirnase had a survival benefit over doxorubicin (11.6 versus 9.6 months). Most patients in the target treatment group had epithelioid histology, performance status 1 and risk category CALGB group 3. The updated analysis at IMIG reported by J von Pawel (Germany) found no change in the median survival results (11.7 versus 9.8 months). An additional analysis using European Organization for Research and Treatment of Cancer (EORTC) risk criteria was applied. A statistically significant survival difference in patients with low-risk features compared to high risk was seen in those who received ranpirnase (15 versus 9 months, P ¼ 0.0063). This study shows that there are individuals that derive clinical benefit from ranpirnase and that this agent has cytostatic activity in mesothelioma. A large international phase III trial (P30-302) comparing doxorubicin to the combination of doxorubicin and ranpirnase is ongoing.
Histone deacetylase inhibitors
The mechanism of action of the antitumor activity of histone deacetylase inhibitors (HDACIs) is unknown. In an early phase I trial that included 13 mesothelioma patients (12 pretreated), LM Krug (USA), found that single agent Suberoylanilide (SAHA) at 300 or 400 mg twice daily dose for 3 consecutive days per week has clinical activity in mesothelioma. S Sharma reported that additional trials using SAHA þ cisplatin/pemetrexed, SAHA þ pemetrexed/bevacizumab and PDX101 are ongoing at the Nevada Cancer Institute, USA.
Proteasome inhibitors
Bortezomib, a proteosome inhibitor, is approved for use in chemotherapy-refractory multiple myeloma, and is under investigation in several solid tumor types. A phase II trial is underway using single agent bortezomib.
Gene therapy D Sterman (USA) reported the results of a phase I trial using intrapleural injections of adenoviral vectors containing IFN-b genes in mesothelioma. Prolonged stabilization of disease (60 days and 6 months) was seen in 2 of 10 patients and toxicity (transient hypoxia and elevation in liver function tests) was mild to moderate.
Additional gene therapy studies are underway in murine xenograft models. K Takahashi (Japan) detected antitumor efficacy with a calponin-targeting herpes simplex virus vector. SS Kim (USA) reported the benefit of SM16, an oral small molecule TGF-b I receptor kinase inhibitor, and intratumoral injection of adenoviral-INF-b therapy. SM16 has been tested in the adjuvant setting in AB12 syngeneic murine models of mesothelioma that were debulked and have immunemediated prevention of recurrence.
Upcoming agents and targets for therapy S Korfee (Germany) found that 17-allylaminodemethoxygeldanamycin (17-AAG) targets the ATP binding region of HSP90 and has preclinical antitumor activity. PW Szlosarek (UK) reported that pegylated arginine deaminase is under investigation in a phase II Eighth International Mesothelioma Interest Group M Carbone et al trial (n ¼ 84) in comparison to best supportive care in chemo-naive patients.
VII. Surgery. Raja Flores and Harvey I Pass
Because there is no universally accepted standard of care for the surgical management of mesothelioma, treatment decisions are strongly influenced by physician bias. The primary goal of surgical resection in this setting is the resection of all gross disease. The choice of operation, extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D) depends on disease stage, pulmonary function, philosophy of the treating physician and type of planned adjuvant therapy.
W Weder (Switzerland) reported that mortality from EPP has decreased from 31-5% in most University Hospitals in Europe. Major complications of EPP were empyema, chylothorax and diaphragmatic or cardiac herniation. M de Perrot et al. (Canada) presented their experience of 55 patients undergoing EPP over a 13-year period and reported that right-sided pneumonectomy was associated with twice as many major complications, including bronchopleural fistulae, when compared to leftsided pneumonectomy. L Zellos and WG Richards (USA), provided data regarding the use of intraoperative hyperthermic cisplatin (50-250 mg/m 2 , 421C) with either sodium thiosulfate or amifostine renal protection after EPP and P/ D. Contrary to historical data, P/D had a significantly higher operative mortality of 11% when compared to EPP. Renal failure, lymphopenia and deep venous thrombosis were the most common complications associated with this regimen. Median survival was 13 months.
RN Taub (USA) is studying the feasibility of administering repeated courses of systemic and intrapleural chemotherapy combined with intrapleural radiation in patients with surgically unresectable early stage mesothelioma. Only five patients have been treated in this manner and further investigation is ongoing.
LM Krug (USA) presented the multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by EPP and high-dose radiotherapy for stages I-III MPM in 71 patients. Chemotherapeutic response rate was 36% and surgical EPP completion rate was 80% (33/41). Evaluation of survival data is ongoing.
VIII. Conclusions
Mesothelioma is one of the most aggressive human malignancies and causes approximately 0. 6% of all cancer deaths. Until recently there was little hope for patients and for those at high risk of developing this cancer. The treatment of mesothelioma will continue to evolve as newer chemotherapeutic agents improve. Multimodality therapy with surgical resection appears to offer the best chance of long-term survival. Recent advancements in our understanding of the pathogenesis of mesothelioma, together with the discovery of novel serological biomarkers in patients with early disease, are leading to novel preventive and therapeutic approaches.
